Elevate your local knowledge
Sign up for the iNFOnews newsletter today!
Tekmira abandons Ebola drug development, changing focus to hepatitis B cure
TORONTO – One month after clinical trials for a once-promising Ebola drug were suspended, the company behind the treatment has suspended all research on the compound.
Tekmira Pharmaceuticals says it has stopped all work on its TKM-Ebola drug and is re-evaluating the contract it signed with the U.S. Department of Defense to develop it.
In a news release, Tekmira says it’s changing its name to Arbutus Biopharma Corp. to reflect its new focus on developing a cure for chronic hepatitis B.
Clinical trials for the TKM-Ebola drug in Sierra Leone were suspended in June after an interim assessment of the project concluded the drug wasn’t showing beneficial results.
The statement Monday offered no comment on the future of a sister drug the company was developing that was designed to fight Marburg fever, which is similar to Ebola.
News from © The Canadian Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Join the Conversation!
Want to share your thoughts, add context, or connect with others in your community?
You must be logged in to post a comment.
